ATE406444T1 - Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung - Google Patents
Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankungInfo
- Publication number
- ATE406444T1 ATE406444T1 AT04076254T AT04076254T ATE406444T1 AT E406444 T1 ATE406444 T1 AT E406444T1 AT 04076254 T AT04076254 T AT 04076254T AT 04076254 T AT04076254 T AT 04076254T AT E406444 T1 ATE406444 T1 AT E406444T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- proteins
- directed
- alzheime
- detection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/474—Pancreatic thread protein; Reg protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5055993A | 1993-04-20 | 1993-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE406444T1 true ATE406444T1 (de) | 2008-09-15 |
Family
ID=21965952
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04076254T ATE406444T1 (de) | 1993-04-20 | 1994-04-20 | Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung |
| AT94915396T ATE312348T1 (de) | 1993-04-20 | 1994-04-20 | Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94915396T ATE312348T1 (de) | 1993-04-20 | 1994-04-20 | Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP0697893B1 (de) |
| JP (2) | JP3513859B2 (de) |
| KR (1) | KR100392244B1 (de) |
| AT (2) | ATE406444T1 (de) |
| CA (1) | CA2161097A1 (de) |
| DE (2) | DE69435136D1 (de) |
| DK (2) | DK0697893T3 (de) |
| ES (2) | ES2255054T3 (de) |
| NZ (1) | NZ266072A (de) |
| PT (1) | PT1564293E (de) |
| WO (1) | WO1994023756A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
| US5936078A (en) * | 1995-12-12 | 1999-08-10 | Kyowa Hakko Kogyo Co., Ltd. | DNA and protein for the diagnosis and treatment of Alzheimer's disease |
| AU1110297A (en) * | 1995-12-12 | 1997-07-03 | Kyowa Hakko Kogyo Co. Ltd. | Novel dnas, novel polypeptides and novel antibodies |
| EP0975651A4 (de) | 1997-02-26 | 2005-03-09 | Gen Hospital Corp | Transgene tiere und zellinien zur erkennung von zur behandlung oder vorbeugung der alzheimerschen krankheit wirksamen medikamente |
| US7226730B1 (en) | 1997-02-26 | 2007-06-05 | The General Hospital Corporation | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease |
| EP1006794B1 (de) | 1997-03-12 | 2007-11-28 | Robert W. Esmond | Verfahren zur behandlung oder prävention der alzheimerischen krankheit |
| EP1541166B1 (de) * | 2001-05-16 | 2007-12-19 | Nymox Corporation | Prävention des Zelltodes durch Verwendung von Segmenten der Neurofilamentproteinen |
| EP1392347B1 (de) * | 2001-05-16 | 2005-08-03 | Nymox Corporation | Prävention des zelltodes durch verwendung der segmente der neurofilamentproteine |
| US6770797B2 (en) | 2001-06-01 | 2004-08-03 | Rhode Island Hospital | Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid |
| EP1714979A3 (de) * | 2001-11-16 | 2007-04-25 | Nymox Corporation | Peptide für die Behandlung von Tumoren und anderen Zuständen, die das entfernen oder zerstören von Zellen erfordern |
| US7317077B2 (en) | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| DK1994152T3 (da) | 2006-02-28 | 2013-03-11 | Nymox Corp | Peptider der er effektive i behandlingen af tumorer og andre tilstande der kræver fjernelse eller destruktion af celler |
| US20080027005A1 (en) * | 2006-07-31 | 2008-01-31 | Paul Averback | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
| US10183058B2 (en) | 2016-06-17 | 2019-01-22 | Nymox Corporation | Method of preventing or reducing the progression of prostate cancer |
| US10172910B2 (en) | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
| US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| US10335453B2 (en) | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
| WO2023217890A1 (en) * | 2022-05-10 | 2023-11-16 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting cfp-elk1 intergene region |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3309972B2 (ja) * | 1988-12-21 | 2002-07-29 | ザ・ジェネラル・ホスピタル・コーポレイション | 神経系疾患または機能障害の検出法 |
-
1994
- 1994-04-20 DK DK94915396T patent/DK0697893T3/da active
- 1994-04-20 DE DE69435136T patent/DE69435136D1/de not_active Expired - Fee Related
- 1994-04-20 NZ NZ266072A patent/NZ266072A/en not_active IP Right Cessation
- 1994-04-20 ES ES94915396T patent/ES2255054T3/es not_active Expired - Lifetime
- 1994-04-20 ES ES04076254T patent/ES2312913T3/es not_active Expired - Lifetime
- 1994-04-20 EP EP94915396A patent/EP0697893B1/de not_active Expired - Lifetime
- 1994-04-20 PT PT04076254T patent/PT1564293E/pt unknown
- 1994-04-20 AT AT04076254T patent/ATE406444T1/de not_active IP Right Cessation
- 1994-04-20 CA CA002161097A patent/CA2161097A1/en not_active Abandoned
- 1994-04-20 JP JP52355694A patent/JP3513859B2/ja not_active Expired - Fee Related
- 1994-04-20 AT AT94915396T patent/ATE312348T1/de not_active IP Right Cessation
- 1994-04-20 DE DE69434844T patent/DE69434844T2/de not_active Expired - Fee Related
- 1994-04-20 DK DK04076254T patent/DK1564293T3/da active
- 1994-04-20 WO PCT/US1994/004321 patent/WO1994023756A1/en active IP Right Grant
- 1994-04-20 EP EP04076254A patent/EP1564293B9/de not_active Expired - Lifetime
- 1994-04-20 KR KR1019950704656A patent/KR100392244B1/ko not_active IP Right Cessation
-
2003
- 2003-10-01 JP JP2003343063A patent/JP2004097227A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0697893A4 (de) | 1996-12-18 |
| CA2161097A1 (en) | 1994-10-27 |
| DE69434844T2 (de) | 2006-12-14 |
| DE69434844D1 (de) | 2006-10-19 |
| NZ266072A (en) | 1997-07-27 |
| JP2004097227A (ja) | 2004-04-02 |
| JPH08509808A (ja) | 1996-10-15 |
| DK0697893T3 (da) | 2006-02-20 |
| ES2255054T3 (es) | 2006-06-16 |
| AU6666994A (en) | 1994-11-08 |
| PT1564293E (pt) | 2008-12-02 |
| EP1564293B9 (de) | 2009-08-19 |
| AU674581B2 (en) | 1997-01-02 |
| WO1994023756A1 (en) | 1994-10-27 |
| KR100392244B1 (ko) | 2003-11-28 |
| ATE312348T1 (de) | 2005-12-15 |
| EP0697893A1 (de) | 1996-02-28 |
| EP1564293A1 (de) | 2005-08-17 |
| EP1564293B1 (de) | 2008-08-27 |
| JP3513859B2 (ja) | 2004-03-31 |
| ES2312913T3 (es) | 2009-03-01 |
| DK1564293T3 (da) | 2009-01-12 |
| DE69435136D1 (de) | 2008-10-09 |
| EP0697893B1 (de) | 2005-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE406444T1 (de) | Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung | |
| EP0442961A4 (en) | Hybrid procoagulant proteins | |
| PT939804E (pt) | Neutroquina alfa | |
| SE8106641L (sv) | Hybrida humanleukocytinterferoner | |
| DE69735375D1 (de) | Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung | |
| DE3786200D1 (de) | Diagnostische verfahren zum nachweis von lymphomen bei menschen. | |
| ATE231551T1 (de) | Huntingtin-dna, protein und verwendung | |
| DE3684295D1 (de) | Antigene proteine und diese enthaltende impfstoffe zur verhuetung von kokzidiose. | |
| ATE301716T1 (de) | Vmp-ähnliche sequenzen von pathogener borrelia | |
| ATE365744T1 (de) | Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen | |
| DE69434926D1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
| DE69635207D1 (de) | Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist. | |
| DK1015477T3 (da) | 32 humane sekreterede proteiner | |
| NO177863C (no) | Fremgangsmåte for fremstilling av rekombinant humant IFN-type I, IFN1, IFN-pseudo-2, -3, og -4, samt ekspresjonsvektorer | |
| KR860006484A (ko) | 단백질 또는 당단백질의 제조방법 | |
| ATE187202T1 (de) | Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung | |
| AU5315790A (en) | Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p. falciparum at the sporozoite stage and in the hepatocytes | |
| NO962596L (no) | Nytt tumorsupressorgen | |
| ATE300554T1 (de) | Bindegewebe-wachstumsfaktor 3. | |
| ZA200207883B (en) | The High Bone Mass Gene of 11Q13.3. | |
| ATE312914T1 (de) | Rdgb-proteine | |
| Schröder et al. | Identification of a novel platelet-derived neutrophil-chemotactic polypeptide with structural homology to platelet-factor 4 | |
| DE69033553D1 (de) | Rekombinante herstellung von laktoperoxidase | |
| EP0839910A3 (de) | Spo-rel, ein relA/spoT Homolog aus Staphylococcus | |
| MX9801603A (es) | Alteraciones geneticas relacionadas con la enfermedad de alzheimer hereditaria. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1564293 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |